Skip to main content
Moderna logo
MRNA.NASDAQ
Moderna
Healthcare · Biotechnology

Biotechnology company pioneering messenger RNA therapeutics and vaccines, gained prominence with COVID-19 vaccine development.

HQ: United StatesListed: United States

Profile & Fundamentals

Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Moderna.

Profile & Fundamentals

Moderna Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA.NASDAQ

Company profile record

Moderna Inc

Common Stock · Healthcare · Biotechnology

Official website

Company

Company / asset
Moderna Inc
Security type
Common Stock
Sector
Healthcare
Industry
Biotechnology
HQ
🇺🇸 United States
Head office
325 Binney Street, Cambridge, MA, United States, 02142

Leadership & scale

Chief executive
Mr. Stéphane Bancel M.B.A.
CEO year born
1973
Full-time employees
4.7K
Fiscal year end
December
IPO date
2018-12-07

Fundamentals snapshot

Updated 2026-07-27
Market Cap
USD 21.7B
P/E
--
Revenue (Q1 26)
USD 389.0M
Profit (Q1 26)
USD -1.3B
Dividend Yield
--
Revenue (FY 25)
USD 1.9B
Shares in public float
370.1M
Insider ownership
7.31%

Reporting & identifiers

Symbol
MRNA.NASDAQ
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US60770K1079
Asset ID
equity_cdc413d2-1e92-5151-9d6b-1cbb7c013976

Ownership

Shares Outstanding

Latest: 395.0M | Max: 431.0M | Min: 61.0M

Shares Outstanding
543.1M407.3M271.5M135.8M0.00
'16
'18
'20
'22
'24
'26

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.